[go: up one dir, main page]

SG10201505606QA - Compounds and methods for kinase modulation, and indications therefor - Google Patents

Compounds and methods for kinase modulation, and indications therefor

Info

Publication number
SG10201505606QA
SG10201505606QA SG10201505606QA SG10201505606QA SG10201505606QA SG 10201505606Q A SG10201505606Q A SG 10201505606QA SG 10201505606Q A SG10201505606Q A SG 10201505606QA SG 10201505606Q A SG10201505606Q A SG 10201505606QA SG 10201505606Q A SG10201505606Q A SG 10201505606QA
Authority
SG
Singapore
Prior art keywords
compounds
methods
kinase modulation
indications therefor
indications
Prior art date
Application number
SG10201505606QA
Inventor
Jiazhong Zhang
Prabha N Ibrahim
Wayne Spevak
James Tsai
Todd Ewing
Ying Zhang
Chao Zhang
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44816304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201505606Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of SG10201505606QA publication Critical patent/SG10201505606QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201505606QA 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor SG10201505606QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32662610P 2010-04-21 2010-04-21

Publications (1)

Publication Number Publication Date
SG10201505606QA true SG10201505606QA (en) 2015-08-28

Family

ID=44816304

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201505606QA SG10201505606QA (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor
SG2012076584A SG184874A1 (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012076584A SG184874A1 (en) 2010-04-21 2011-04-20 Compounds and methods for kinase modulation, and indications therefor

Country Status (39)

Country Link
US (3) US8901118B2 (en)
EP (1) EP2560972B1 (en)
JP (2) JP5808793B2 (en)
KR (1) KR101799126B1 (en)
CN (1) CN102947305B (en)
AR (2) AR080940A1 (en)
AU (1) AU2011242778B2 (en)
BR (1) BR112012026927A2 (en)
CA (1) CA2796998C (en)
CL (1) CL2012002937A1 (en)
CO (1) CO6620045A2 (en)
CR (1) CR20120536A (en)
CY (1) CY1120554T1 (en)
DK (1) DK2560972T3 (en)
EA (1) EA028105B1 (en)
EC (1) ECSP12012245A (en)
ES (1) ES2641643T3 (en)
GE (1) GEP20156251B (en)
HR (1) HRP20171660T1 (en)
HU (1) HUE036461T2 (en)
IL (1) IL222498A (en)
LT (1) LT2560972T (en)
MA (1) MA34229B1 (en)
MX (1) MX336056B (en)
MY (1) MY160780A (en)
NZ (2) NZ703538A (en)
PE (1) PE20130240A1 (en)
PH (1) PH12012502103A1 (en)
PL (1) PL2560972T3 (en)
PT (1) PT2560972T (en)
RS (1) RS56588B1 (en)
SG (2) SG10201505606QA (en)
SI (1) SI2560972T1 (en)
SM (1) SMT201700458T1 (en)
TW (2) TWI619713B (en)
UA (1) UA109128C2 (en)
UY (1) UY33346A (en)
WO (1) WO2011133637A2 (en)
ZA (1) ZA201207898B (en)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
BRPI0814423B1 (en) 2007-07-17 2022-04-19 Plexxikon, Inc Kinase modulating compounds and pharmaceutical composition comprising the same
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
PT2725028T (en) 2008-10-22 2016-08-31 Array Biopharma Inc Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of trk kinase inhibitors
MY160737A (en) 2009-04-03 2017-03-15 Hoffmann La Roche Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
SG10201407129SA (en) 2009-11-06 2014-12-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2012005827A (en) 2009-11-18 2012-06-19 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
WO2011079133A2 (en) 2009-12-23 2011-06-30 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI619713B (en) * 2010-04-21 2018-04-01 普雷辛肯公司 Compounds and methods for kinase regulation and their indications
HUE044025T2 (en) 2010-05-20 2019-09-30 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
CN103517710B (en) 2011-02-07 2017-05-31 普莱希科公司 For the compound of kinases regulation
EA201391239A1 (en) 2011-04-05 2014-03-31 Пфайзер Лимитед PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS AN INHIBITOR INHIBITORS KNAZA
SG194847A1 (en) 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014018888A1 (en) 2012-07-26 2014-01-30 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment
CN104981247A (en) 2012-09-06 2015-10-14 普莱希科公司 Compounds and methods for kinase modulation, and indications therefor
EP2903986A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Tropomyosin-related kinase inhibitors
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
US9676748B2 (en) 2012-12-21 2017-06-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
DK2970265T3 (en) 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
RU2015149937A (en) 2013-05-30 2017-07-06 Плексксикон Инк. COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
EP3027655B1 (en) 2013-07-30 2019-08-21 Blueprint Medicines Corporation Ntrk2 fusions
CA2934010A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
PT4176894T (en) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
ES2774177T3 (en) 2014-09-15 2020-07-17 Plexxikon Inc Heterocyclic compounds and uses of these
FI3699181T3 (en) 2014-11-16 2023-03-28 Array Biopharma Inc CRYSTAL FORM (S)-N-(5-((R)-2-(2,5-DILUORIPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3- FROM HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROSULPHATE
US20180263945A1 (en) * 2014-12-19 2018-09-20 Research Institute At Nationwide Children's Hospital Pyruvate compounds for treatment of peripheral neuropathy
KR20170103838A (en) 2015-01-23 2017-09-13 컨플루언스 라이프 사이언시스, 인코포레이티드 Heterocyclic itk inhibitors for treating inflammation and cancer
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3581573B1 (en) * 2015-05-06 2022-07-06 Plexxikon Inc. Synthesis of a compound that modulates kinases
SG10201912355TA (en) 2015-05-06 2020-02-27 Plexxikon Inc Solid forms of a compound modulating kinases
WO2016191295A1 (en) 2015-05-22 2016-12-01 Plexxikon Inc. Solid forms of a compound for modulating kinases
MX2017015461A (en) 2015-06-01 2018-08-15 Loxo Oncology Inc Methods of diagnosing and treating cancer.
PL3322706T3 (en) 2015-07-16 2021-07-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN108137585B (en) 2015-09-21 2021-10-22 普莱希科公司 Heterocyclic compounds and their applications
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
SG11201804711RA (en) 2015-12-07 2018-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
AU2017232610B2 (en) 2016-03-16 2021-07-22 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
CA3019661A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65987B1 (en) 2016-04-04 2024-10-31 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
TW201740951A (en) * 2016-05-11 2017-12-01 貝達醫藥公司 2-aniline pyrimidine as a therapeutic agent for the treatment of brain cancer
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CA3034010A1 (en) 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US20180153922A1 (en) 2016-12-06 2018-06-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
WO2018136202A2 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
TWI752155B (en) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS
TWI674260B (en) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 Aryl hydrocarbon receptor (ahr) modulator compounds
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
CA3070505C (en) 2017-07-25 2023-09-26 Plexxikon Inc. Formulations of a compound modulating kinases
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI876442B (en) 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN112165958A (en) 2017-10-27 2021-01-01 普莱希科公司 Formulations of compounds for modulating kinases
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019157119A1 (en) * 2018-02-07 2019-08-15 University Of Cincinnati System and method for detecting small blood-tissue barrier disruption
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
KR102129114B1 (en) 2018-07-26 2020-07-02 주식회사 온코파마텍 A compound having TrkA inhibitory activity, and a pharmaceutical composition for preventing or treating pain containing the compound as an active ingredient
CN117281803A (en) 2018-07-31 2023-12-26 罗索肿瘤学公司 Spray-dried dispersions and formulations
CN110833557A (en) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 Use of pyrazolopyrimidine derivatives for the treatment of tubular nephritis
CN110833552A (en) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 Use of pyrazolopyrimidine derivatives for the treatment of lupus nephritis
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
IL280984B2 (en) 2018-08-22 2025-02-01 Cullgen Shanghai Inc Tropomyosin receptor kinase (trk) degradation compounds and methods of use
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (en) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド 7-((3,5-dimethoxyphenyl) amino) quinoxaline derivative as an FGFR inhibitor for treating cancer
TW202104221A (en) 2019-04-09 2021-02-01 美商普雷辛肯公司 Compounds and methods for ep300 or cbp modulation and indications therefor
CN110643672A (en) * 2019-10-15 2020-01-03 西安交通大学 Medical application of high-expression TrkB as novel target point in inhibiting pancreatic cancer metastasis
EP4110772A4 (en) 2020-02-26 2024-04-03 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
AU2021261383A1 (en) 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
CN115605460A (en) 2020-04-29 2023-01-13 普莱希科公司（Us） Synthesis of heterocyclic compounds
AU2021329301A1 (en) 2020-08-18 2023-04-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
MX2023002037A (en) 2020-08-18 2023-06-12 Incyte Corp Process and intermediates for preparing a jak inhibitor.
AU2021327375A1 (en) 2020-08-21 2023-03-16 Opna Bio SA Combinational drug anticancer therapies
AU2021348592B2 (en) * 2020-09-25 2024-08-08 Jumbo Drug Bank Co., Ltd. 1h-pyrrolo[2,3-c]pyridine compounds and application thereof
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
CN114920744B (en) * 2021-11-16 2024-05-07 中国药科大学 Non-covalent BTK kinase inhibitor and biological application thereof
JP7762460B2 (en) * 2022-03-25 2025-10-30 成都嘉葆薬銀医薬科技有限公司 Crystalline form of 1H-pyrrolo[2,3-c]pyridine compound and its production method
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
EA006153B1 (en) 2000-06-26 2005-10-27 Пфайзер Продактс Инк. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
GB0107368D0 (en) * 2001-03-23 2001-05-16 Novartis Ag Organic compounds
EP1392300A1 (en) * 2001-05-11 2004-03-03 Vertex Pharmaceuticals Incorporated 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
PL218692B1 (en) 2002-01-22 2015-01-30 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US20040171062A1 (en) 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20040142864A1 (en) 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US20050048573A1 (en) 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
SE0300456D0 (en) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
US20050170431A1 (en) 2003-02-28 2005-08-04 Plexxikon, Inc. PYK2 crystal structure and uses
US20050079548A1 (en) 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
AU2004255934B2 (en) 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
AU2004259738B2 (en) 2003-07-17 2011-11-17 Plexxikon, Inc. PPAR active compounds
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US7517970B2 (en) 2003-12-19 2009-04-14 Plexxikon, Inc. Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
PT1696920E (en) 2003-12-19 2015-01-14 Plexxikon Inc Compounds and methods for development of ret modulators
DK1713806T3 (en) * 2004-02-14 2013-08-05 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
EP1724271A4 (en) * 2004-02-26 2013-01-23 Kyowa Hakko Kirin Co Ltd Preventive and/or therapeutic agent for neutrophilic inflammation disease
EP1742627A4 (en) 2004-05-06 2009-08-26 Plexxikon Inc Pde4b inhibitors and uses therefor
WO2005116035A1 (en) 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006009755A2 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
JP2008521831A (en) 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド PPAR active compounds
JP2008521829A (en) 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド PPAR active compounds
US20060160135A1 (en) 2004-12-08 2006-07-20 Weiru Wang SF-1 and LRH-1 modulator development
KR20080027775A (en) 2005-05-17 2008-03-28 플렉시콘, 인코퍼레이티드 Pyrrole (2,3-pyri) pyridine derivative protein kinase inhibitor
UA93679C2 (en) * 2005-05-17 2011-03-10 Плексикон, Инк. Compounds modulating c-kit and c-fms activity and uses therefor
PL1893612T3 (en) 2005-06-22 2012-01-31 Plexxikon Inc Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
AU2006287528A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds
BRPI0615948A2 (en) 2005-09-07 2011-05-31 Plexxikon Inc ppar active compound, its composition, its kit and its use
NZ567162A (en) 2005-09-07 2011-06-30 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as PPAR modulators
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (en) 2006-12-21 2012-08-24 Plexxikon Inc PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS
JP2010514695A (en) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド Compounds and methods for kinase regulation and indications therefor
PE20090159A1 (en) 2007-03-08 2009-02-21 Plexxikon Inc INDOL-PROPIONIC ACID DERIVED COMPOUNDS AS PPARs MODULATORS
MX2009009290A (en) 2007-03-08 2009-09-10 Plexxikon Inc Ppar active compounds.
BRPI0811517A2 (en) * 2007-05-04 2014-11-18 Irm Llc COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS.
BRPI0814423B1 (en) 2007-07-17 2022-04-19 Plexxikon, Inc Kinase modulating compounds and pharmaceutical composition comprising the same
JO3240B1 (en) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv Inhibitors of c-fms Kinase
AU2009217356B2 (en) * 2008-02-22 2012-05-03 Irm Llc Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors
WO2009115084A2 (en) 2008-03-20 2009-09-24 Schebo Biotech Ag Novel pyrrolopyrimidine derivatives and the use thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (en) 2008-05-19 2009-12-16 Plexxikon Inc PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
EP2313411A1 (en) 2008-06-10 2011-04-27 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor
PT2384326E (en) 2008-08-20 2014-06-09 Zoetis Llc Pyrrolo[2,3-d]pyrimidine compounds
PT2725028T (en) 2008-10-22 2016-08-31 Array Biopharma Inc Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of trk kinase inhibitors
US8129404B2 (en) 2009-03-11 2012-03-06 Plexxikon Inc. Compounds and uses thereof
WO2010104945A1 (en) 2009-03-11 2010-09-16 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
MY160737A (en) 2009-04-03 2017-03-15 Hoffmann La Roche Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
SG175877A1 (en) 2009-05-04 2011-12-29 Plexxikon Inc Compounds and methods for inhibition of renin, and indications therefor
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
SG10201407129SA (en) 2009-11-06 2014-12-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2012005827A (en) 2009-11-18 2012-06-19 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
WO2011079133A2 (en) 2009-12-23 2011-06-30 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
TWI619713B (en) * 2010-04-21 2018-04-01 普雷辛肯公司 Compounds and methods for kinase regulation and their indications
US8642606B2 (en) 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
CN103517710B (en) 2011-02-07 2017-05-31 普莱希科公司 For the compound of kinases regulation
SG194847A1 (en) 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN104981247A (en) 2012-09-06 2015-10-14 普莱希科公司 Compounds and methods for kinase modulation, and indications therefor
US9676748B2 (en) 2012-12-21 2017-06-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
DK2970265T3 (en) 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
RU2015149937A (en) 2013-05-30 2017-07-06 Плексксикон Инк. COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Also Published As

Publication number Publication date
UY33346A (en) 2011-10-31
MX2012012197A (en) 2012-12-17
PE20130240A1 (en) 2013-03-04
US8901118B2 (en) 2014-12-02
TWI619713B (en) 2018-04-01
EA028105B1 (en) 2017-10-31
WO2011133637A2 (en) 2011-10-27
AR080940A1 (en) 2012-05-16
SG184874A1 (en) 2012-11-29
LT2560972T (en) 2017-10-25
PH12012502103A1 (en) 2016-04-01
AU2011242778B2 (en) 2015-09-03
BR112012026927A2 (en) 2017-10-10
PT2560972T (en) 2017-10-09
ES2641643T3 (en) 2017-11-10
EP2560972A2 (en) 2013-02-27
ECSP12012245A (en) 2012-11-30
AR115233A2 (en) 2020-12-09
CN102947305A (en) 2013-02-27
CL2012002937A1 (en) 2013-01-25
NZ603087A (en) 2015-01-30
TWI510487B (en) 2015-12-01
SI2560972T1 (en) 2017-12-29
HRP20171660T1 (en) 2017-12-15
TW201544506A (en) 2015-12-01
TW201136929A (en) 2011-11-01
CY1120554T1 (en) 2019-07-10
GEP20156251B (en) 2015-02-25
CR20120536A (en) 2013-02-01
MY160780A (en) 2017-03-15
DK2560972T3 (en) 2017-11-27
KR101799126B1 (en) 2017-11-17
CN102947305B (en) 2016-07-06
MX336056B (en) 2016-01-07
EA201290973A1 (en) 2013-04-30
AU2011242778A1 (en) 2012-11-22
RS56588B1 (en) 2018-02-28
ZA201207898B (en) 2016-09-28
KR20130066621A (en) 2013-06-20
US20110263595A1 (en) 2011-10-27
NZ703538A (en) 2016-11-25
IL222498A (en) 2016-10-31
CO6620045A2 (en) 2013-02-15
JP2016028073A (en) 2016-02-25
JP5808793B2 (en) 2015-11-10
US20170283423A1 (en) 2017-10-05
US9682981B2 (en) 2017-06-20
SMT201700458T1 (en) 2017-11-15
MA34229B1 (en) 2013-05-02
UA109128C2 (en) 2015-07-27
US20150183793A1 (en) 2015-07-02
PL2560972T3 (en) 2018-01-31
CA2796998C (en) 2019-03-05
EP2560972B1 (en) 2017-09-20
JP2013525363A (en) 2013-06-20
HUE036461T2 (en) 2018-07-30
EP2560972A4 (en) 2013-11-20
CA2796998A1 (en) 2011-10-27
WO2011133637A3 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
ZA201207898B (en) Compounds and methods for kinase modulation,and indications therefor
ZA201305856B (en) Compounds and methods for kinase modulation,and indications therefor
EP2892534B8 (en) Compounds and methods for kinase modulation, and indications therefor
IL219567A0 (en) Compounds and methods for kinase modulation, and indications therefor
IL219418A0 (en) Compounds and methods for kinase modulation, and indications therefor
EP2516438A4 (en) Compounds and methods for kinase modulation, and indications therefor
ZA201504872B (en) Compounds and methods for kinase modulation, and indications therefor
SG10201607813SA (en) Compounds and methods for kinase modulation, and indications therefor
IL229371A0 (en) Kinase modulation and indications therefor
IL239959A0 (en) Compounds for methods for kinase modulation, and indications therefor
EP2609733A4 (en) Techniques for object based operations
GB201122205D0 (en) SIM locking
GB201009731D0 (en) Kinase inhibitors
GB2481490B (en) Techniques for customization
GB201108825D0 (en) Morpholino compounds, uses and methods
HK1175651A (en) Compounds and methods for kinase modulation, and indications therefor
HK1177744A (en) Compounds and methods for kinase modulation, and indications therefor
HK1182899A (en) Chemical compounds, compositions and methods for kinase modulation
GB201010976D0 (en) Antibody modulation
GB201011150D0 (en) Antibody modulation